{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:06:45Z","timestamp":1762146405803,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,4,1]],"date-time":"2004-04-01T00:00:00Z","timestamp":1080777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008392","name":"Sundhed og Sygdom, Det Frie Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003035","name":"Aase og Ejnar Danielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003035","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI49213-02"],"award-info":[{"award-number":["AI49213-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007438","name":"Familien Hede Nielsens Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009708","name":"Novo Nordisk Fonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009708","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2004,4]]},"DOI":"10.1016\/j.yexcr.2003.11.029","type":"journal-article","created":{"date-parts":[[2004,1,30]],"date-time":"2004-01-30T05:15:37Z","timestamp":1075439737000},"page":"91-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Changes in protein expression in p53 deleted spontaneous thymic lymphomas"],"prefix":"10.1016","volume":"295","author":[{"given":"Bent","family":"Honor\u00e9","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Vorum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders Elm","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f8ren","family":"Buus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mogens H","family":"Cla\u00ebsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexcr.2003.11.029_BIB1","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1038\/312646a0","article-title":"Participation of p53 cellular tumour antigen in transformation of normal embryonic cells","volume":"312","author":"Eliyahu","year":"1984","journal-title":"Nature"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB2","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1432-1033.1986.tb09449.x","article-title":"Analysis of human p53 proteins and mRNA levels in normal and transformed cells","volume":"154","author":"Matlashewski","year":"1986","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gad.4.1.1","article-title":"p53: oncogene or anti-oncogene?","volume":"4","author":"Lane","year":"1990","journal-title":"Genes Dev."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/gcc.2870040102","article-title":"TP53 tumor suppressor gene: a model for investigating human mutagenesis","volume":"4","author":"Caron de Fromentel","year":"1992","journal-title":"Genes, Chromosomes Cancer"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB5","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1126\/science.1905840","article-title":"p53 mutations in human cancers","volume":"253","author":"Hollstein","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB6","first-page":"415","article-title":"TP53 tumor suppressor gene: structure and function","volume":"vol. 4","author":"Jerry","year":"2002"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB7","first-page":"4759","article-title":"Role of p53 and apoptosis in carcinogenesis","volume":"19","author":"Wang","year":"1999","journal-title":"Anticancer Res."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0960-9822(00)00002-6","article-title":"Tumor spectrum analysis in p53-mutant mice","volume":"4","author":"Jacks","year":"1994","journal-title":"Curr. Biol."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB9","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/1521-4141(200104)31:4<1239::AID-IMMU1239>3.0.CO;2-C","article-title":"Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity","volume":"31","author":"Mathiassen","year":"2001","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-8518-1-1","article-title":"Tumor-associated antigens identified by mRNA expression profiling as tumor rejection epitopes","volume":"1","author":"Andersen","year":"2003","journal-title":"J. Immune Based Ther. Vaccines"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB11","series-title":"Nature","first-page":"579","article-title":"Transcriptomics and proteomics: integration?","volume":"vol. 5","author":"Honor\u00e9","year":"2003"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB12","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1093\/rheumatology\/40.7.750","article-title":"Monoclonal antibodies against human ribosomal P proteins penetrate into living cells and cause apoptosis of Jurkat T cells in culture","volume":"40","author":"Sun","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB13","first-page":"131","article-title":"V(D)J recombination is not required for the development of lymphoma in p53-deficient mice","volume":"9","author":"Nacht","year":"1998","journal-title":"Cell Growth Differ."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB14","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1101\/gad.10.16.2038","article-title":"V(D)J recombination activates a p53-dependent DNA damage checkpoint in scid lymphocyte precursors","volume":"10","author":"Guidos","year":"1996","journal-title":"Genes Dev."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB15","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1084\/jem.183.4.1923","article-title":"p53 prevents maturation to the CD4+ CD8+ stage of thymocyte differentiation in the absence of T cell receptor rearrangement","volume":"183","author":"Jiang","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1074-7613(00)80084-9","article-title":"Pre-TCR signaling and inactivation of p53 induces crucial cell survival pathways in pre-T cells","volume":"11","author":"Haks","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB17","doi-asserted-by":"crossref","first-page":"6408","DOI":"10.1093\/nar\/17.15.6408","article-title":"The mouse homologue of the human acidic ribosomal phosphoprotein PO: a highly conserved polypeptide that is under translational control","volume":"17","author":"Krowczynska","year":"1989","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB18","first-page":"3067","article-title":"Increased expression of human ribosomal phosphoprotein P0 messenger RNA in hepatocellular carcinoma and colon carcinoma","volume":"52","author":"Barnard","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB19","first-page":"4990","article-title":"Identification and characterization of genes associated with human hepatocellular carcinogenesis","volume":"59","author":"Kondoh","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB20","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1093\/protein\/15.4.287","article-title":"Prediction of proteasome cleavage motifs by neural networks","volume":"15","author":"Kesmir","year":"2002","journal-title":"Protein Eng."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB21","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1002\/eji.1830260836","article-title":"Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding","volume":"26","author":"Stryhn","year":"1996","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1046\/j.1365-3083.2003.01182.x","article-title":"Self-peptides with intermediate capacity to bind and stabilize MHC Class I molecules may be immunogenic","volume":"57","author":"Andersen","year":"2003","journal-title":"Scand. J. Immunol."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1093\/carcin\/13.2.259","article-title":"Expression of ribosomal phosphoprotein PO is induced by antitumor agents and increased in Mer-human tumor cell lines","volume":"13","author":"Grabowski","year":"1992","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB24","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ijc.10226","article-title":"Cancer chemoresistance: the relationship between p53 and multidrug transporters","volume":"98","author":"Bush","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB25","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1093\/carcin\/23.10.1603","article-title":"Regulation of the Mdr1 isoforms in a p53-deficient mouse model","volume":"23","author":"Bush","year":"2002","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB26","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1074-7613(00)80066-7","article-title":"The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes","volume":"10","author":"Vonderheide","year":"1999","journal-title":"Immunity"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB27","doi-asserted-by":"crossref","first-page":"11993","DOI":"10.1073\/pnas.92.26.11993","article-title":"Targeting p53 as a general tumor antigen","volume":"92","author":"Theobald","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB28","first-page":"5508","article-title":"High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes","volume":"60","author":"Vierboom","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB29","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/elps.1150180333","article-title":"A comparison of selected mRNA and protein abundances in human liver","volume":"18","author":"Anderson","year":"1997","journal-title":"Electrophoresis"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB30","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1128\/MCB.19.3.1720","article-title":"Correlation between protein and mRNA abundance in yeast","volume":"19","author":"Gygi","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.yexcr.2003.11.029_BIB31","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1002\/1615-9861(200108)1:8<1022::AID-PROT1022>3.0.CO;2-7","article-title":"The effects of transcription regulating genes PDR1, pdr1-3 and PDR3 in pleiotropic drug resistance","volume":"1","author":"Nawrocki","year":"2001","journal-title":"Proteomics"},{"key":"10.1016\/j.yexcr.2003.11.029_BIB32","first-page":"15","article-title":"Altered protein synthesis in p53 null and hemizygous transgenic mouse embryonic fibroblasts","volume":"5","author":"He","year":"1995","journal-title":"Appl. Theor. Electrophor."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482703006360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482703006360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:03:34Z","timestamp":1762146214000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482703006360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["S0014482703006360"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2003.11.029","relation":{},"ISSN":["0014-4827"],"issn-type":[{"type":"print","value":"0014-4827"}],"subject":[],"published":{"date-parts":[[2004,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Changes in protein expression in p53 deleted spontaneous thymic lymphomas","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2003.11.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}